Corcept Therapeutics Incorporated (CORT)
Upgrades & Downgrades
Latest CORT news
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
18 September 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)
26 August 2023
Corcept Therapeutics' equity stock shows promising investment prospects with the resolution of its Korlym overhang and strong financial performance. The outcome of the trial against Teva Pharmaceutica...
Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio
25 August 2023
Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.
Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View
3 August 2023
Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host...
26 July 2023
MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on...
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
4 May 2023
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call Transcript
3 May 2023
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Offi...
Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates
3 May 2023
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.20 per share a year ago.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
2 May 2023
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host ...
26 April 2023
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on...